The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti‐tumor necrosis factor therapy

Anti‐tumor necrosis factor‐alpha (anti‐TNF) therapies are associated with severe mycobacterial infections in rheumatoid arthritis patients. We developed and validated electronic record search algorithms for these serious infections.

[1]  P. Polgreen,et al.  Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  K. Winthrop,et al.  Nontuberculous Mycobacteria Infections and Anti–Tumor Necrosis Factor-α Therapy , 2009, Emerging infectious diseases.

[3]  A. A. Drosos,et al.  Epidemiology of rheumatoid arthritis. , 2004, Autoimmunity reviews.

[4]  M. Weisman,et al.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010 , 2011, Annals of the rheumatic diseases.

[5]  S. Suissa,et al.  Antirheumatic drugs and the risk of tuberculosis. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  T. Marras,et al.  Nontuberculous Mycobacterial Lung Infections in Ontario, Canada: Clinical and Microbiological Characteristics , 2010, Lung.

[7]  K. Winthrop,et al.  Preventing and treating biologic-associated opportunistic infections , 2009, Nature Reviews Rheumatology.

[8]  S. Schneeweiss,et al.  Veteran's affairs hospital discharge databases coded serious bacterial infections accurately. , 2007, Journal of clinical epidemiology.

[9]  B. Bresnihan,et al.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009 , 2009, Annals of the rheumatic diseases.

[10]  S. Ehlers.  Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Robert Horsburgh,et al.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.

[12]  R. Long,et al.  Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. , 2003, The Lancet. Infectious diseases.

[13]  F. Wolfe,et al.  A brief introduction to the National Data Bank for Rheumatic Diseases. , 2005, Clinical and experimental rheumatology.

[14]  K. Winthrop,et al.  Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Richard Platt,et al.  Pharmacy Data for Tuberculosis Surveillance and Assessment of Patient Management , 2004, Emerging infectious diseases.

[16]  R S Wallis,et al.  Granulomatous infectious diseases associated with tumor necrosis factor antagonists. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  K. Winthrop,et al.  Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. , 2010, American journal of respiratory and critical care medicine.

[18]  Case definitions for infectious conditions under public health surveillance. Centers for Disease Control and Prevention. , 1997, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.